Prognostic value and targeted inhibition of survivin expression in esophageal adenocarcinoma and cancer-adjacent squamous epithelium

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Malhotra, Usha ^a   Zaidi, Ali H ^c   Kosovec, Juliann E ^c   Kasi, Pashtoon M ^b   Komatsu, Yoshihiro ^c   Rotoloni, Christina L ^c   Davison, Jon M ^b   Irvin, Clint R ^c   Hoppo, Toshitaka ^c   Nason, Katie S ^b   Kelly, Lori A ^c   Gibson, Michael K ^b   Jobe, Blair A ^c  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c ALLEGHENY HEALTH NETWORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; FLUOROURACIL; FORMALDEHYDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PARAFFIN; PLATINUM COMPLEX; SMALL INTERFERING RNA; SURVIVIN;

ADJUVANT THERAPY; ADULT; AGED; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; CANCER ADJACENT SQUAMOUS EPITHELIUM; CANCER CELL CULTURE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; EMBEDDING; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS RESECTION; FEMALE; FROZEN SECTION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; MALE; PREDICTION; PREDICTIVE VALUE; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SQUAMOUS EPITHELIUM; TISSUE FIXATION; UPREGULATION; VERY ELDERLY; WESTERN BLOTTING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POLY(ADP-RIBOSE) POLYMERASES; PROGNOSIS; RISK FACTORS; RNA, SMALL INTERFERING; SURVIVAL ANALYSIS; TISSUE FIXATION; TUMOR MICROENVIRONMENT;

EID: 84892617818     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078343     Document Type: Article

References (30)

1. Wani S, Falk G, Hall M, Gaddam S, Wang A, et al. (2011) Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinoma. Clin Gastroenterol Hepatol 9: 220-227; quiz e226.
2. Bandla S, Pennathur A, Luketich JD, Beer DG, Lin L, et al. (2012) Comparative genomics of esophageal adenocarcinoma and squamous cell carcinoma. Ann Thorac Surg 93: 1101-1106.
3. Chang E, Donahue J, Smith A, Hornick J, Rao JN, et al. (2010) Loss of p53, rather than beta-catenin overexpression, induces survivin-mediated resistance to apoptosis in an esophageal cancer cell line. J Thorac Cardiovasc Surg 140: 225-232.
4. Grimminger P, Vallbohmer D, Hoffmann A, Schulte C, Bollschweiler E, et al. (2009) Quantitative analysis of survivin RNA expression in blood as a noninvasive predictor of response to neoadjuvant radiochemotherapy in esophageal cancer. J Surg Oncol 100: 447-451.
5. Reid BJ, Prevo LJ, Galipeau PC, Sanchez CA, Longton G, et al. (2001) Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol 96: 2839-2848.
6. Pohl H, Welch HG (2005) The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 97: 142-146.
7. Hoffmann AC, Vallbohmer D, Grimminger P, Metzger R, Prenzel KL, et al. (2010) Preoperative survivin mRNA detection in peripheral blood is an independent predictor of outcome in esophageal carcinoma. Pharmacogenomics 11: 341-347.
8. Kato J, Kuwabara Y, Mitani M, Shinoda N, Sato A, et al. (2001) Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer 95: 92-95.
9. Rosato A, Pivetta M, Parenti A, Iaderosa GA, Zoso A, et al. (2006) Survivin in esophageal cancer: An accurate prognostic marker for squamous cell carcinoma but not adenocarcinoma. Int J Cancer 119: 1717-1722.
10. Altieri DC (2003) Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 22: 8581-8589.
11. Beardsmore DM, Verbeke CS, Davies CL, Guillou PJ, Clark GW (2003) Apoptotic and proliferative indexes in esophageal cancer: predictors of response to neoadjuvant therapy [corrected]. J Gastrointest Surg7: 77-86; discussion 86-77.
12. Vallbohmer D, Peters JH, Oh D, Kuramochi H, Shimizu D, et al. (2005) Survivin, a potential biomarker in the development of Barrett's adenocarcinoma. Surgery138: 701-706; discussion 706-707.
13. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, et al. (1998) IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 58: 5315-5320.
14. Kelly RJ, Lopez-Chavez A, Citrin D, Janik JE, Morris JC (2011) Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin. Mol Cancer 10: 35.
15. Altieri DC (2003) Validating survivin as a cancer therapeutic target. Nature Reviews Cancer 3: 46-54.
16. Fukuda S, Pelus LM (2001) Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34+ cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis. Blood 98: 2091-2100.
17. Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nature medicine 3: 917-921.
18. Vetter CS, Müller-Blech K, Schrama D, Bröcker EB, Becker JC (2005) Cytoplasmic and nuclear expression of survivin in melanocytic skin lesions. Archives of dermatological research 297: 26-30.
19. Chiou SK, Moon WS, Jones MK, Tarnawski AS (2003) Survivin expression in the stomach: implications for mucosal integrity and protection. Biochemical and biophysical research communications 305: 374-379.
20. Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, et al. (2002) Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 21: 2613-2622.
21. Upadhyay R, Khurana R, Kumar S, Ghoshal UC, Mittal B (2011) Role of survivin gene promoter polymorphism (-31G>C) in susceptibility and survival of esophageal cancer in northern India. Ann Surg Oncol 18: 880-887.
22. Ngan CY, Yamamoto H, Takagi A, Fujie Y, Takemasa I, et al. (2008) Oxaliplatin induces mitotic catastrophe and apoptosis in esophageal cancer cells. Cancer Sci 99: 129-139.
23. Kaur P, Kallakury BS, Sheehan CE, Fisher HA, Kaufman RP Jr, et al. (2004) Survivin and Bcl-2 expression in prostatic adenocarcinomas. Arch Pathol Lab Med 128: 39-43.
24. Shen X, Zheng JY, Shi H, Zhang Z, Wang WZ (2012) Survivin knockdown enhances gastric cancer cell sensitivity to radiation and chemotherapy in vitro and in nude mice. Am J Med Sci 344: 52-58.
25. Cao M, Yie SM, Wu SM, Chen S, Lou B, et al. (2009) Detection of survivin-expressing circulating cancer cells in the peripheral blood of patients with esophageal squamous cell carcinoma and its clinical significance. Clin Exp Metastasis 26: 751-758.
26. Ogawa R, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A, et al. (2009) Expression profiling of micro-RNAs in human esophageal squamous cell carcinoma using RT-PCR. Med Mol Morphol 42: 102-109.
27. Dhir R, Patel AA, Winters S, Bisceglia M, Swanson D, et al. (2008) A multidisciplinary approach to honest broker services for tissue banks and clinical data: a pragmatic and practical model. Cancer 113: 1705-1715.
28. Zhu H, Wang Q, Hu C, Zhang W, Quan L, et al. (2011) High expression of survivin predicts poor prognosis in esophageal squamous cell carcinoma following radiotherapy. Tumour Biol 32: 1147-1153.
29. Hamoui N, Peters JH, Schneider S, Uchida K, Yang D, et al. (2004) Increased acid exposure in patients with gastroesophageal reflux disease influences cyclooxygenase-2 gene expression in the squamous epithelium of the lower esophagus. Arch Surg139: 712-716; discussion 716-717.
30. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, et al. (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366: 883-892.